title: Growth of Escherichia coli in propofol, lidocaine, and mixtures of propofol and lidocaine.
abstract: BACKGROUND
  Microorganisms grow rapidly in propofol. Extrinsic contamination of propofol is thought to be a source of postoperative sepsis and wound infection. We studied growth of a strain of Escherichia coli in thiopental, propofol, lidocaine, and mixtures of propofol and lidocaine.
  
  
  METHODS
  The pathogen was exposed to 2.5% thiopental; 1.0% propofol; 1.0%, 2.0% and 4.0% preservative-free lidocaine; and propofol solutions containing 0.25%, 0.5%, 1.0%, 2.0%, or 4.0% lidocaine for 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, and 24 h at room temperature, respectively. The inocula from these suspensions were cultured for 48 h at 37 degrees C after the antimicrobial activity of the local anesthetics in the inocula was inactivated by a 1:1000 dilution with distilled water.
  
  
  RESULTS
  No organisms grew after exposure to 2.5% thiopental. The exposure of E. coli to propofol increased the colony count to approximately 90 times the control count. The colony counts of E. coli after exposure to 1.0%, 2.0% and 4.0% lidocaine and 0.25%, 0.5%, 1.0%, 2.0% and 4.0% lidocaine in 1.0% propofol were lower than the counts after exposure to 1.0% propofol (P = 0.0048, 0.0027, 0.0003, 0.0503, 0.0188, 0.0080, 0.0044, and 0.0001, respectively). The growth rate of the microorganism was significantly higher in cultures exposed to 1.0% propofol than that in cultures exposed to lidocaine alone or lidocaine-propofol mixtures (P < 0.0001, respectively).
  
  
  CONCLUSIONS
  Lidocaine possesses bacteriostatic activity against E. coli. Addition of lidocaine to propofol confers its bacteriostatic activity to the mixture and may decrease the hazard of infection associated with the extrinsic contamination of propofol.
authors.affiliation: Department of Anesthesiology, School of Medicine, Fukuoka University, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Sakuragi
authors.forename: K
authors.initials: K
authors.lastname: Yanagisawa
authors.forename: Y
authors.initials: Y
authors.lastname: Shirai
authors.forename: K
authors.initials: K
authors.lastname: Dan
mesh_terms: D018686:Anesthetics, Intravenous / Q000008:administration & dosage / Q000494:pharmacology*; D000779:Anesthetics, Local / Q000008:administration & dosage / Q000494:pharmacology*; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D015169:Colony Count, Microbial; D004338:Drug Combinations; D004340:Drug Contamination; D004926:Escherichia coli / Q000187:drug effects / Q000254:growth & development*; D004927:Escherichia coli Infections; D006801:Humans; D008012:Lidocaine / Q000008:administration & dosage / Q000494:pharmacology*; D011183:Postoperative Complications; D015742:Propofol / Q000008:administration & dosage / Q000494:pharmacology*; D018805:Sepsis / Q000382:microbiology; D013530:Surgical Wound Infection / Q000382:microbiology; D013696:Temperature; D013874:Thiopental / Q000008:administration & dosage / Q000494:pharmacology
chemical_list: D018686:Anesthetics, Intravenous; D000779:Anesthetics, Local; D000900:Anti-Bacterial Agents; D004338:Drug Combinations; D008012:Lidocaine; D013874:Thiopental; D015742:Propofol